- Molecular NameCarbidopa
- SynonymAlpha-Methyldopahydrazine; C-DOPA; Carbidopa Anhydrous; Carbidopa Monohydrate; Carbidopum [INN-Latin]; MK-486; N-Aminomethyldopa
- Weight226.232
- Drugbank_IDDB00190
- ACS_NO28860-95-9
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-2.04
- pkaN/A
- LogD (pH=7, predicted)-4.53
- Solubility (experiment)0.0038 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.62
- LogSw (predicted, AB/LogsW2.0)21.27
- Sw (mg/ml) (predicted, ACD/Labs)4.27
- No.of HBond Donors6
- No.of HBond Acceptors6
- No.of Rotatable Bonds4
- TPSA115.81
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa.
- Absorption_valueN/A
- Absorption (description)Readily but incompletely absorbed after oral administration. Rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding36.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmDecarboxylated to dopamine in extracerebral tissues
- Half life2 h
- ExcretionAbout 50% of an oral dose is excreted in the urine in 48 h and 47% is eliminated in the faeces. Of the urinary material, about 30% is unchanged drug, 10 to 14% is 2-(4-hydroxy-3-methoxybenzyl)propionic acid, 10% is 2-(3,4-dihydroxybenzyl)propionic acid, 5% is 3,4-dihydroxyphenylacetone and 10% is 2-(3-hydroxybenzyl)propionic acid. The metabolites are excreted mainly as glucuronide conjugates.
- Urinary Excretion5.3
- Clerance18 ml/min/kg
- ToxicitySymptoms of a carbidopa toxicity include muscle spasms or weakness, spasms of the eyelid, nausea, vomiting, diarrhea, an irregular heartbeat, confusion, agitation, hallucinations, and unconsciousness.
- LD50 (rat)N/A
- LD50 (mouse)N/A